ProNAi Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The potentially profitable idea in ProNAi's portfolio is an approach the drug development community overlooked--taking direct aim at a diseased cell's DNA in order to suppress a disease pathway. ProNAi will use nucleic acid interfering technology (DNAi) to develop drugs across a broad spectrum of genetic diseases, but it intends to file its first INDs for prostate cancer and non-Hodgkin's lymphoma.